dsRNA Targeting E6AP Gene for HPV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HPV infections, such as cervical cancer and genital warts, are inadequate as they do not effectively inhibit the progression of high-risk HPV subtypes, which display significant genotypic diversity, and existing therapies lack broad-spectrum efficacy.
Innovation Solution
The use of double-stranded ribonucleic acid (dsRNA) molecules that target and silence the E6AP gene, essential for HPV proliferation, by inhibiting gene expression through RNA interference, with specific sequences complementary to the E6AP mRNA transcript, achieving significant reduction in gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for HPV infections, then treatment is provided for symptomatic lesions, but the treatments do not effectively inhibit the progression of high-risk HPV subtypes and lack broad-spectrum efficacy
Solution Approach 1:
The dsRNA molecule is designed to target the E6AP gene, which is universally required by all high-risk HPV subtypes for proliferation. This single therapeutic agent provides broad-spectrum efficacy across diverse HPV subtypes (HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, etc.) by interfering with a conserved host factor that all these viruses depend on, rather than requiring separate treatments for each viral subtype.
Solution Approach 2:
The invention introduces E6AP dsRNA as an intermediary molecule that mediates the inhibition of HPV proliferation. The dsRNA acts as a mediator between the therapeutic intervention and the viral replication process by specifically binding to E6AP mRNA and preventing translation of the E6AP protein, which is essential for HPV E6 oncoprotein function and viral propagation.
2Reliability
If dsRNA molecules are used to target E6AP gene, then gene expression is inhibited by at least 40%, but the complexity of RNA interference mechanism increases
Solution Approach 1:
The dsRNA molecule utilizes the cell's endogenous RNA interference machinery to achieve gene silencing. Once the dsRNA enters the cell, it automatically engages with the cellular Dicer enzyme and RISC complex to process and execute the silencing of E6AP mRNA. The therapeutic agent essentially serves itself by harnessing the host cell's own molecular machinery, eliminating the need for complex external delivery systems or additional therapeutic components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA molecules effectively inhibit E6AP gene expression by at least 40%, providing a therapeutic approach to treat HPV-associated diseases like cervical cancer and genital warts, with potential for broad-spectrum efficacy against diverse HPV subtypes.
Implementation Method 1
The use of double-stranded ribonucleic acid (dsRNA) molecules that target and silence the E6AP gene, essential for HPV proliferation, by inhibiting gene expression through RNA interference
Data Source
AI summary
The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.